Once-daily raltegravir: an effective first-line option for HIV

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • 1200 mg once daily (QD) raltegravir (Isentress HD) administered with tenofovir disoproxil fumarate and emtricitabine (Atripla) in treatment-naive patients with HIV-1 demonstrates noninferiority to raltegravir 400 mg twice daily (BID; including rapid virological suppression and su...